People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vanqua Bio, Inc. | — | Biotechnology | Series C | $136.0M | $462.4M | 2021 |
| Enlaza Therapeutics, Inc. | — | Pharmaceuticals | Series C | $134.6M | $87.6M | 2024 |
| Compass Therapeutics LLC | — | Biotechnology | Series D+ | $132.6M | $900.7M | 2015 |
| Arvinas, Inc. | — | Biotechnology | Series C | $129.1M | $1.3B | 2015 |
| Averna Therapeutics Inc. | — | Pharma | Series C | $85.0M | $805.0M | 2024 |
| Gennao Bio, Inc. | — | Biotechnology | Series B | $47.5M | $211.6M | 2021 |
| UCAN Co | — | Biotechnology | Series A | $21.5M | $119.7M | 2009 |
| SpringWorks Therapeutics, LLC | — | Pharma | Series A | $12.8M | $396.9M | 2017 |
Stephen Squinto at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Squinto on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 2 | 24 |
| ANDREW LEVIN | 1 | 17 |
| Peter Thompson | 1 | 16 |
| James Topper | 1 | 12 |
| Shelley Chu | 1 | 10 |
| Kush Parmar | 1 | 10 |
| Jonathan Silverstein | 1 | 10 |
| Tim Shannon | 1 | 9 |
| Chau Khuong | 1 | 9 |
| Ben Auspitz | 1 | 9 |
| Errik Anderson | 1 | 8 |
| Dylan Morris | 1 | 8 |
| Sean Cassidy | 1 | 7 |
| Michal Silverberg | 1 | 7 |
| Daniel Lynch | 1 | 7 |
| Henry Chen | 1 | 7 |
| Jay Lichter | 1 | 7 |
| Tighe Reardon | 1 | 7 |
| James Sullivan | 1 | 7 |
| Philip J. Ferneau | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.